[ReWalk in GlobeNewswire] Advancement in ReWalk technology achieves FDA clearance as only personal exoskeleton to enable use on stairs and curbs

MARLBOROUGH, Mass. and BERLIN and YOKNEAM ILIT, Israel, March 07, 2023 (GLOBE NEWSWIRE) — ReWalk Robotics Ltd., (Nasdaq: RWLK) (“ReWalk” or the “Company”), a leading provider of innovative technologies that enable mobility and wellness in rehabilitation and daily life for individuals with neurological conditions, announced today that its innovative ReWalk Personal Exoskeleton technology has received clearance from the Food and Drug Administration (“FDA”) for use on stairs and curbs in the United States, making it the only personal exoskeleton to receive FDA clearance for this indication.

Read more here.